Integra LifeSciences (NASDAQ:IART) Reaches New 1-Year Low – Time to Sell?

Integra LifeSciences Holdings Corporation (NASDAQ:IART) hit a new 52-week low during trading on Wednesday . The stock traded as low as $10.60 and last traded at $10.8950, with a volume of 126648 shares changing hands. The stock had previously closed at $10.98.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on the stock. Citigroup reduced their target price on shares of Integra LifeSciences from $12.00 to $11.00 and set a “sell” rating for the company in a research note on Friday, October 31st. Truist Financial reaffirmed a “hold” rating and issued a $13.00 price objective (down previously from $15.00) on shares of Integra LifeSciences in a research note on Monday, November 3rd. Weiss Ratings reissued a “sell (e+)” rating on shares of Integra LifeSciences in a research report on Monday, December 29th. JPMorgan Chase & Co. raised their target price on Integra LifeSciences from $12.00 to $13.00 and gave the company an “underweight” rating in a report on Friday, October 31st. Finally, Wall Street Zen upgraded Integra LifeSciences from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. Two analysts have rated the stock with a Buy rating, two have assigned a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat.com, Integra LifeSciences has a consensus rating of “Reduce” and a consensus price target of $15.00.

Integra LifeSciences Trading Up 4.7%

The company has a quick ratio of 1.80, a current ratio of 3.14 and a debt-to-equity ratio of 1.73. The company has a 50-day moving average price of $12.28 and a 200-day moving average price of $13.26. The company has a market capitalization of $881.71 million, a price-to-earnings ratio of -1.75 and a beta of 1.04.

Institutional Investors Weigh In On Integra LifeSciences

Hedge funds have recently modified their holdings of the business. Rubric Capital Management LP grew its stake in shares of Integra LifeSciences by 1.3% in the fourth quarter. Rubric Capital Management LP now owns 7,753,934 shares of the life sciences company’s stock worth $96,304,000 after acquiring an additional 100,000 shares during the last quarter. Dimensional Fund Advisors LP grew its position in Integra LifeSciences by 9.2% in the 3rd quarter. Dimensional Fund Advisors LP now owns 3,184,726 shares of the life sciences company’s stock worth $45,634,000 after purchasing an additional 267,134 shares during the last quarter. State Street Corp increased its holdings in shares of Integra LifeSciences by 0.8% during the 4th quarter. State Street Corp now owns 2,812,615 shares of the life sciences company’s stock worth $34,933,000 after purchasing an additional 21,717 shares during the period. Paradigm Capital Management Inc. NY raised its position in shares of Integra LifeSciences by 5.3% during the fourth quarter. Paradigm Capital Management Inc. NY now owns 2,664,998 shares of the life sciences company’s stock valued at $33,099,000 after buying an additional 135,198 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in shares of Integra LifeSciences by 8.8% in the fourth quarter. Geode Capital Management LLC now owns 1,683,964 shares of the life sciences company’s stock valued at $20,918,000 after buying an additional 135,743 shares during the period. 84.78% of the stock is owned by institutional investors.

About Integra LifeSciences

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.